Patrick Groothuis

Patrick Groothuis

Company: Byondis

Job title: Principal Scientist - In Vivo Pharmacology, Toxicology, Drug Metabolism & Pharmacokinetics


Preclinical Profile of SYD1875, a Novel Site- Specifically Conjugated Anti- 5T4 Antibody Drug Conjugate 8:30 am

• SYD1875 comprises a humanized, HC41-cysteine-engineered IgG1 monoclonal antibody that targets 5T4 • SYD1875 is site-specifically conjugated to a proprietary cleavable synthetic duocarmycin-based linker-drug (vc-seco- DUBA), which yields a homogeneous and stable ADC with favorable physicochemical properties and manufacturability • SYD1875 is a potent ADCnwith anti-tumor activity in multiple solid tumor types with high, moderate…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.